

# Vittorio Gebbia

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1844088/vittorio-gebbia-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78  
papers

8,743  
citations

29  
h-index

79  
g-index

79  
ext. papers

9,801  
ext. citations

4.5  
avg, IF

4.31  
L-index

#	Paper	IF	Citations
78	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , <b>2021</b> , 21, 549	4.8	0
77	Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis. <i>Future Science OA</i> , <b>2021</b> , 7, FSO750	2.7	0
76	Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis. <i>Ecancermedicalscience</i> , <b>2020</b> , 14, 1113	2.7	1
75	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , <b>2019</b> , 133, 62-68	5.9	1
74	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. <i>Lung Cancer</i> , <b>2017</b> , 108, 15-21	5.9	7
73	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , <b>2017</b> , 8, 57528-57536	3.3	7
72	Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. <i>Tumori</i> , <b>2016</b> , 102, 108-13	1.7	1
71	Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 910-5	2.2	262
70	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. <i>Lung Cancer</i> , <b>2013</b> , 81, 77-83	5.9	36
69	Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 390-8	4.9	32
68	Impact of use of Oral Anticancer Drugs on Activity of Italian Oncology Practices: Results of a Survey Conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , <b>2013</b> , 99, 35-38	1.7	2
67	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1830-1844	8.9	17
66	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , <b>2012</b> , 13, 239-46	21.7	3985
65	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3002-11	2.2	193
64	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , <b>2012</b> , 76, 457-64	5.9	14
63	Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11 Suppl 1, S49-59	4.1	29
62	Does pain intensity predict a poor opioid response in cancer patients?. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 713-7	7.5	15

61	Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE). <i>Clinical Lung Cancer</i> , <b>2011</b> , 12, 402-6	4.9	7
60	Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3628-35	2.2	149
59	Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1645-51	2.2	237
58	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , <b>2010</b> , 67, 86-92	5.9	19
57	First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. <i>Lung Cancer</i> , <b>2010</b> , 69, 218-24	5.9	11
56	Anticancer oral therapy: emerging related issues. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36, 595-605	14.4	115
55	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 735-43	7.5	60
54	Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. <i>Clinical Journal of Pain</i> , <b>2010</b> , 26, 794-7	3.5	38
53	Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 461-4	2.7	39
52	Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1836-43	2.2	137
51	Evolution of therapy decision-making process for advanced non-small cell lung cancer. <i>Oncology</i> , <b>2009</b> , 77 Suppl 1, 97-102	3.6	1
50	Adjuvant therapy in colon cancer. <i>Oncology</i> , <b>2009</b> , 77 Suppl 1, 50-6	3.6	11
49	Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. <i>Lung Cancer</i> , <b>2009</b> , 63, 251-8	5.9	26
48	Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. <i>Journal of Pain</i> , <b>2009</b> , 10, 594-600	5.2	51
47	Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). <i>Lung Cancer</i> , <b>2008</b> , 61, 369-77	5.9	33
46	Correlation between basal bilirubin levels and survival in advanced colorectal carcinoma treated with CPT-11-based chemotherapy: A study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 94-99	1.6	
45	Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 1321-37	4	3
44	Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. <i>European Journal of Pain</i> , <b>2008</b> , 12, 1040-6	3.7	105

43	Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. <i>Drugs</i> , <b>2007</b> , 67, 1403-10	12.1	29
42	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology, The</i> , <b>2007</b> , 8, 500-12	21.7	80
41	Oral vinorelbine may not induce acute pain at the tumor site. <i>Journal of Pain and Symptom Management</i> , <b>2006</b> , 32, 197-9	4.8	7
40	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. <i>BMC Cancer</i> , <b>2006</b> , 6, 202	4.8	18
39	Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 5, 422-8	3.8	23
38	Treatment of metastatic breast cancer with vinorelbine and docetaxel. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2006</b> , 29, 276-80	2.7	5
37	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. <i>Lancet Oncology, The</i> , <b>2005</b> , 6, 669-77	21.7	177
36	Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1815-23	2.2	394
35	Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4866-75	2.2	576
34	Oral versus intravenous vinorelbine: clinical safety profile. <i>Expert Opinion on Drug Safety</i> , <b>2005</b> , 4, 915-28	4.1	55
33	Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma. <i>Breast Cancer Research and Treatment</i> , <b>2003</b> , 77, 99-108	4.4	4
32	Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1013-21	8.7	22
31	Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. <i>Lung Cancer</i> , <b>2003</b> , 39, 179-89	5.9	41
30	Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 362-72	9.7	673
29	Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 3025-34	2.2	211
28	Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. <i>Cancer</i> , <b>2002</b> , 94, 902-910	6.4	319
27	Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study. <i>Lung Cancer</i> , <b>2002</b> , 37, 179-87	5.9	20
26	Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofoinic acid and infusional fluorouracil: results of a multicenter phase II study. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 4089-91	2.2	113

25	5-Fluorouracil and levofolonic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma. <i>Cancer</i> , <b>1999</b> , 85, 535-545	6.4	15
24	Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1999</b> , 22, 262-6	2.7	5
23	Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study. <i>Cancer</i> , <b>1997</b> , 79, 1394-400	6.4	10
22	Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolonic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). <i>Cancer</i> , <b>1996</b> , 78, 1300-7	6.4	34
21	Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1996</b> , 19, 278-80	2.7	8
20	Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1996</b> , 19, 589-91	2.7	2
19	Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. <i>Oncology</i> , <b>1995</b> , 52, 41-4	3.6	19
18	Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1995</b> , 18, 293-6	2.7	8
17	Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. <i>Cancer</i> , <b>1995</b> , 76, 535-6	6.4	2
16	Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. <i>Cancer</i> , <b>1995</b> , 76, 1821-8	6.4	22
15	Mitomycin $\square$ C $\square$ and Vinorelbine as Second Line Chemotherapy for Metastatic Breast Carcinoma. <i>Tumori</i> , <b>1994</b> , 80, 33-36	1.7	6
14	Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. <i>Cancer</i> , <b>1994</b> , 74, 1945-52	6.4	62
13	A phase I-II study of cyclophosphamide, epidoxorubicin, levofolonic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. <i>Acta Oncologica</i> , <b>1994</b> , 33, 925-9	3.2	2
12	Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Orl</i> , <b>1994</b> , 56, 279-82	2	5
11	Weekly levofolonic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1994</b> , 17, 485-9	2.7	5
10	Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1994</b> , 17, 160-2	2.7	7
9	A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , <b>1993</b> , 29A, 1358-9	7.5	30
8	A phase II study of levofolonic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma. <i>Oncology</i> , <b>1993</b> , 50, 490-4	3.6	9

7	Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. <i>Anti-Cancer Drugs</i> , <b>1993</b> , 4, 443-5	2.4	44
6	Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy. <i>Anti-Cancer Drugs</i> , <b>1992</b> , 3, 347-9	2.4	6
5	Cisplatin in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma. <i>Cancer Investigation</i> , <b>1992</b> , 10, 497-504	2.1	5
4	High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1992</b> , 118, 458-62	4.9	8
3	Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer. <i>Medical Oncology and Tumor Pharmacotherapy</i> , <b>1992</b> , 9, 165-8		4
2	Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1991</b> , 117, 266-8	4.9	4
1	Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1989</b> , 115, 579-82	4.9	10